Oral Microbiome–Host Epigenetic Interactions in Oral Carcinogenesis: A Molecular Perspective
- 1Department of Medical Microbiology, Faculty of Medicine, Istanbul Atlas University, 34408 Istanbul, Türkiye
- 2Department of Medical Microbiology, Faculty of Medicine, Kırklareli University, 39100 Kirklareli, Türkiye
Abstract
Oral squamous cell carcinoma is still found late, and the tumor microenvironment is complicated enough that treatment often fails even when the diagnosis is timely. While genetic mutations partially account for this pathogenesis, they do not fully explain tumor behavior. Attention has therefore shifted to the microbial community around the tumor, which appears to contribute to malignancy less through the genome than through the host epigenome. This review is about the mechanism rather than about cataloging which species are present. We follow what Porphyromonas gingivalis, Fusobacterium nucleatum and Candida albicans do to DNA methylation, histone modification and non-coding RNA expression in host cells. While chronic inflammation plays a well-established role, bacterial and fungal metabolites also reach chromatin directly, and the resulting changes silence tumor suppressors and release oncogenic signaling in epithelium and stroma alike. We then ask what this means for tumor heterogeneity, for immune escape, and for progression, and we close with the two clinical questions that follow: whether salivary microbial and methylation signatures are usable for early detection, and whether epigenetic drugs can be aimed at the microbial component of the oral tumor microenvironment. In conclusion, the oral microbiome–epigenome axis acts as a crucial driver of tumor progression and microenvironmental immunosuppression. While translating these mechanistic insights into clinical practice necessitates rigorous in vivo validation, integrating microbiota-directed interventions with epigenetic therapies represents a highly promising frontier for the early detection and comprehensive management of OSCC.
Related
- Epigenetic phase variation in the gut microbiome enhances bacterial adaptation
- New perspective on epigenetic modification and immunotherapy in endometrial cancer.
- Epigenetic Rewiring of Enhancer–Promoter Interactions in Cancer: Mechanisms and Therapeutic Implications
- Designing fiber–gut microbiome interactions with active learning
- Reprogramming the gut–brain axis in neurodegeneration: comparative microbiome, metabolite, immunometabolic, polyphenol, probiotic, and epigenetic mechanisms in Alzheimer’s and Parkinson’s diseases
BibTeX
@article{unlu2026oral,
title = {{Oral Microbiome–Host Epigenetic Interactions in Oral Carcinogenesis: A Molecular Perspective}},
author = {Ozge Unlu and Mehmet Demirci},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219791},
url = {https://www.mdpi.com/1422-0067/27/21/9791},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Oral Microbiome–Host Epigenetic Interactions in Oral Carcinogenesis: A Molecular Perspective
AU - Ozge Unlu
AU - Mehmet Demirci
PY - 2026
DA - 2026/10/31
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219791
UR - https://www.mdpi.com/1422-0067/27/21/9791
AB - Oral squamous cell carcinoma is still found late, and the tumor microenvironment is complicated enough that treatment often fails even when the diagnosis is timely. While genetic mutations partially account for this pathogenesis, they do not fully explain tumor behavior. Attention has therefore shifted to the microbial community around the tumor, which appears to contribute to malignancy less through the genome than through the host epigenome. This review is about the mechanism rather than about cataloging which species are present. We follow what Porphyromonas gingivalis, Fusobacterium nucleatum and Candida albicans do to DNA methylation, histone modification and non-coding RNA expression in host cells. While chronic inflammation plays a well-established role, bacterial and fungal metabolites also reach chromatin directly, and the resulting changes silence tumor suppressors and release oncogenic signaling in epithelium and stroma alike. We then ask what this means for tumor heterogeneity, for immune escape, and for progression, and we close with the two clinical questions that follow: whether salivary microbial and methylation signatures are usable for early detection, and whether epigenetic drugs can be aimed at the microbial component of the oral tumor microenvironment. In conclusion, the oral microbiome–epigenome axis acts as a crucial driver of tumor progression and microenvironmental immunosuppression. While translating these mechanistic insights into clinical practice necessitates rigorous in vivo validation, integrating microbiota-directed interventions with epigenetic therapies represents a highly promising frontier for the early detection and comprehensive management of OSCC.
SN - 1422-0067
ER -